Biopharma and Competition - Pharma Rep Focus

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

MedCity News

NOVEMBER 25, 2024

But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March. The post FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug appeared first on MedCity News.

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

Health Economics and Outcomes Research: Biopharma’s Underappreciated Value Creator

Trending Sources

The New Radiopharma Competition Requires Unprecedented Medical Logistics

Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi

Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking

Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas

New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds

Why and How To Achieve Effective Data Management Strategies Early in the Biopharma Lifecycle

Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still Competitive

Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test

FTC Orders Illumina to Divest Grail, Says Deal Stifles Cancer Test Competition

Ionis Rare Disease Drug Is Headed to FDA, But Forthcoming Data Will Decide Competitive Profile

FTC Sees Red Over Alleged Misuse of FDA Orange Book, Puts 10 Pharmas on Notice

Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator

Sanofi drops out of competitive breast cancer drug race after another trial failure

How Startup miRecule Leveraged Its RNA Platform Tech to Land a Sanofi Alliance

Innovation key for boosting UK biopharma competitiveness

Top 5 regulatory trends impacting Software as a Medical Device (SaMD)

Cytokinetics Heart Drug’s Trial Data Look Competitive With BMS Med Camzyos

FTC order could ease biopharma competition

Which Healthcare Startups Won the MedCity INVEST Pitch Perfect Contest?

FDA Approves Roche Lymphoma Drug, Bringing Competition to New AbbVie Med

Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda

Amarin Restructures, Charting Course That Braces for Generic Competition

JPM24: Amgen CEO hopes to take a bite of competitive obesity market with unique approach

Sanofi’s FDA Nod in Hemophilia Gives Patients More Convenience, Brings Roche New Competition

FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen

TheracosBio Drug Approval Puts It in Competition With Blockbuster Diabetes Meds

FDA Approval of Pfizer Alopecia Drug Brings New Competition to Eli Lilly Med

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies

Evaluating benefits of outsourcing biopharma R&D

How Will Walgreens’ Expansion into Specialty Pharmacy Affect the Industry?

CMS Touts First Negotiated Drug Prices, But Greater Impact Expected in Future Rounds

Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck

Pharma Just Increased the Price of Hundreds of Drugs. PBMs are Minimizing the Impact for Health Plans, Employers and Patients

Neurocrine Commits $175M to Voyager in New Neuro Gene Therapy Alliance

Biopharma struggling to find talent with adequate digital skills

Biogen Bows Out of Acorda Pact on MS Med; Focus Turns to New Growth Drivers

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency

Neuro Drug Passed Up by Biogen Posts Positive Data for Ionis, Setting Stage for Phase 3 Test

Amgen to Buy Horizon Therapeutics for $28B, Edging Out Sanofi in Bidding War

Structure Raises $300M as Oral GLP-1 Drug’s Data Keep Up With Pfizer, Eli Lilly

Metabolic Meds Biotech Kailera Launches With $400M for Next-Generation Weight-Loss Drugs

Sanofi Abandons Deal for Rare Disease Drug Amid FTC’s Monopoly Concerns

Stay Connected